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Case Report
Cephalosporin resistant Shigella flexneri from a clinical isolate - a rare finding
Nasim Sabir, Afia Zafar 
Department of Pathology and Microbiology, The Aga Khan University, Karachi, Pakistan.
Abstract
Shigellosis is an important public health problem,
especially in developing countries. Antibiotic treatment of
dysentery aimed at resolving diarrhea or reducing its dura-
tion, and to prevent transmission to other close contacts.
Isolates with resistance to first line drugs have been report-
ed throughout world, third generation cephalosporins and
quinolones are mainstay of treatment. Shigella flexneri
resistant to third generation cephalosporins in a clinical iso-
late is a rare finding, and this has been reported for the first
time in Pakistan.
Introduction
Infection due to Shigella species is an important
cause of diarrhea worldwide and is responsible for signifi-
cant morbidity and mortality in the underdeveloped world
including Pakistan.1,2 Frequency of antibiotic resistance
among Shigella species is on the rise like many other bacte-
rial pathogens.3 Resistance to drugs frequently used in
enteric infections like ampicillin, tetracyclines, chloram-
phenicol and co-trimoxazole has been reported in Shigella
flexneri and sonnei.4
Production of β-lactamase enzymes is primarily
responsible for the development of resistance against 
β-lactam antibiotics. Presence of TEM-1, OXA-1 and
OXA-3 β-lactamase have been reported in Shigella spp.
rendering resistance to all 1st, 2nd and 3rd generation
cephalosporins.5-7 In a recent publication, Fortineau et al
reported a case of bloody diarrhea in an Algerian boy
caused by Shigella flexneri, resistant to all β-lactam drugs,
and the isolate expressed extended spectrum β-lactamase
(ESBL) production. The isolate was found to be containing
SHV2 β-lactam gene.1 A similar SHV-2 β-lactamase pro-
ducing strain of Shigella dysentriae has been reported from
India, which was resistant to 3rd generation cephalosporins
as well as to oxacillin and oxyimenocephalosorins.5
Another case report of vulvovaginitis in a prepuber-
tal child due to Shigella flexneri has been published, the
organism was susceptible to Cefixime, Amoxicillin/clavu-
lanic acid and Levofloxacin in vitro but the patient remained
unresponsive to the treatment with cefixime and amoxi-
cillin/clavulanic acid for 10 and 14 days respectively and
eventually responded to prolonged therapy with
Ciprofloxacin.6
We report a case of an old man admitted into the hos-
pital with the diagnosis of stroke and volvulus, Shigella
flexneri was isolated from his stool sample, and found to be
resistant to all 1st, 2nd and 3rd generation cephalosporins sus-
ceptible only to fluroquinolones and imepenem.
Case History
A 73 years old male with a 10-15 years history of
hypertension, ischemic heart disease and chronic obstruc-
tive pulmonary disease, suddenly developed tonic colonic
seizures during an outpatient visit. The patient was admitted
after initial management. Previous history revealed transient
attacks of unconsciousness for which he had frequently
been admitted to the hospital.
Investigations showed a right frontal hematoma on CT
scan. Considering a primary diagnosis of meningoencephalitis,
intravenous ceftriaxone and acyclovir were initiated.
Abdominal distension associated with severe abdominal pain
developed on the 2nd day of admission and an abdominal X-ray
revealed a sigmoid volvulus. Volvulus was decompressed by
urgent sigmoidoscopy and a rectal tube was inserted. The loose
stool found in the gut was sent for detail report (D/R) and cul-
ture and sensitivity. The patient continued to pass loose stools
from rectal tube with the frequency of 3-4 times a day and also
developed low-grade fever.
Stool D/R reported presence of moderate pus cells.
Stool cultures were set up on standard microbiological cul-
ture media and standard microbiological methods were fol-
lowed for the isolation of diarrheal pathogens.
The organism isolated from stool culture was bio-
chemically identified by Analytic profile index (API) 20E
(bio Murex, France) serotyped by anti-sera supplied by
Denka Seiken Co., Japan and found to be Shigella flexneri
Co., Type-2. Anti-microbial susceptibility was determined
using disc diffusion in accordance with NCCLS guidelines.
The isolate was found resistant to ampicillin, chlorampheni-
col, ceftriaxone, cefixime, and susceptible to ofloxacin and
imepenam. Minimum inhibitory concentration (MIC) was
also determined for ceftriaxone by usingE-strip (AB
Biodisk, Sweden) which was 32 µg, suggestive of interme-
diate resistance. 
Extended spectrum β-lactamase (ESBL) production
was detected by combined disc diffusion method applying
cefotaxime (30 µg) and cefotaxime plus clavulanate 
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(30 µg + 10 µg) discs according to NCCLS. Our isolate was
negative for ESBL production.
Injection imipenam was commenced and clinical
response was observed. Within 24 hours fever deffervescence
and improvement in the frequency and consistency of stool
was seen. Simultaneously, his abdominal discomfort was
relieved and rectal tube was removed.
Though the patient improved promptly after initia-
tion of imipenem, he remained hospitalized for his primary
illness and was later discharged. No further incidence of
abdominal symptoms occurred during his stay.
Discussion
Like many other pathogens multiple antibiotic resist-
ant Shigellae has been on the rise. In countries like Pakistan
the impact can be serious, due to the acute nature of illness
in an infected population, spread of resistance to other
enteric pathogens and also due to the non-availability of
efficient and structured healthcare facilities to the public.  
Being a tertiary care center, the Aga Khan University
receives around 4,300 stool samples per annum for culture
and sensitivity testing per year, and the average isolation
rate of stool pathogens is 17% with Shigella 11% of all. To
our knowledge this is the first isolate of Shigella flexneri
found resistant to ceftriaxone and cefixime in the country. 
Presence of toxic mega colon has been reported with
Shigella dysentriae isolates due to presence of Shigga
toxin.7 Shigella flexneri have been reported to possess very
potent shigella enterotoxins (SHET 1 and 2),8 but produc-
tion of shigga toxin has not been reported. An association of
sigmoid volvulus with presence of Shigella flexneri could
not be confirmed, as colonic tissue sample was not submit-
ted for routine microbiological culture. The presence of
multidrug resistant shigella in a patient without a previous
history of diarrheal illness, but with a history of multiple
hospital admissions and previous antibiotic exposure may
be the cause of antimicrobial resistance. A long-term carri-
er state could not be ruled out in this case. 
Most cases of shigella dysentery are self-limiting
and usually an antibiotic treatment is not recommended but
cases in extreme of ages or in compromised patients may
need effective and early therapy. Presence of cephalosporin
resistant shigella may pose a great problem in the future,
due to prevalence of isolates resistant to Ampicillin,
Chloramphenicol, Tetracyclines and Cotrimoxazole
(MDR). Cephalosporins are antibiotics of choice for severe
and hospitalized cases, particularly in children where
quinolones are not considered as treatment options by most
clinicians. Recent reports of ESBL producing and quinolone
resistant shigella from different parts of the world make the
situation bleaker with limited treatment options.9,10
Therefore, this report again reinforces the need of
active and effective surveillance program as matter of
utmost priority at national level to detect various MDR iso-
lates. At the same time it would assist the development of
effective strategies which are needed for the control plans.
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